Page last updated: 2024-12-06
cefpimizole
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
cefpimizole: semisynthetic cephalosporin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 68597 |
| CHEMBL ID | 2103902 |
| CHEBI ID | 135868 |
| SCHEMBL ID | 49108 |
| MeSH ID | M0125127 |
Synonyms (32)
| Synonym |
|---|
| 84880-03-5 |
| ac 1370 |
| u 63196e |
| cpiz |
| CHEBI:135868 |
| cefpimizole |
| 2-[1-[[(6r,7r)-2-carboxy-7-[[(2r)-2-[(5-carboxy-1h-imidazole-4-carbonyl)amino]-2-phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]pyridin-1-ium-4-yl]ethanesulfonate |
| cefpimizolum [latin] |
| cefpimizole [usan:inn] |
| cefpimizol |
| cefpimizol [spanish] |
| 24s58uhu7n , |
| u 63,196 |
| 1-(((6r,7r)-2-carboxy-7-((r)-2-(5-carboxyimidazole-4-carboxamido)-2-phenylacetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-4-(2-sulfoethyl)pyridinium hydroxide, inner salt |
| pyridinium, 1-((2-carboxy-7-(((((5-carboxy-1h-imidazol-4-yl)carbonyl)amino)phenylacetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-4-(2-sulfoethyl)-, hydroxide, inner salt, (6r-(6alpha,7beta(r*)))- |
| u-63,196 |
| u 63196 |
| cefpimizolum |
| unii-24s58uhu7n |
| CHEMBL2103902 |
| u-63196 |
| cefpimizole [mi] |
| cefpimizole [usan] |
| pyridinium, 1-((2-carboxy-7-(((((5-carboxy-1h-imidazol-4-yl)carbonyl)amino)phenylacetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-4-(2-sulfoethyl)-, hydroxide, inner salt, (6r-(6.alpha.,7.beta.(r*)))- |
| cefpimizole [who-dd] |
| cefpimizole [inn] |
| 1-[[(6r,7r)-2-carboxy-7-[(r)-2-(5-carboxyimidazole-4-carboxamido)-2-phenylacetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-4-(2-sulfoethyl)pyridinium hydroxide, inner salt |
| SCHEMBL49108 |
| 1-{[(6r,7r)-2-carboxy-7-{[(2r)-2-{[(5-carboxy-1h-imidazol-4-yl)(hydroxy)methylidene]amino}-1-hydroxy-2-phenylethylidene]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}-4-(2-sulfonatoethyl)pyridin-1-ium |
| 2-(1-(((6r,7r)-2-carboxy-7-((r)-2-(5-carboxy-1h-imidazole-4-carboxamido)-2-phenylacetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl)pyridinium-4-yl)ethanesulfonate |
| Q5057293 |
| gtpl10779 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Because VCM has the adverse reaction of nephrotoxicity, we are apprehensive about using VCM with other antibiotics, which might increase this problem." | ( [Nephrotoxicity and drug interaction of vancomycin (2)]. Nakagawa, Y; Toyoguchi, T, 1996) | 0.29 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| " Therefore, the nephrotoxic effects and pharmacokinetics of VCM were examined in rabbits and compared with those in rabbits administered with VCM and other antibiotics." | ( [Nephrotoxicity and drug interaction of vancomycin (2)]. Nakagawa, Y; Toyoguchi, T, 1996) | 0.29 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Cefpimizole was well tolerated locally and systemically by all the subjects at all administered dosage levels." | ( Tolerance and disposition of cefpimizole in normal human volunteers after intramuscular administration. Lakings, DB; Novak, E; Paxton, LM, 1987) | 1.47 |
| " dosing for 6 or 11 days." | ( Pharmacokinetics and dose proportionality of cefpimizole in normal humans after intramuscular administration. Friis, JM; Lakings, DB; Lunan, CM; Novak, E; Paxton, LM, 1986) | 0.53 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| peptide | Amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (19)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1079943 | Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] | |||
| AID1079931 | Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] | |||
| AID1079949 | Proposed mechanism(s) of liver damage. [column 'MEC' in source] | |||
| AID1079942 | Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] | |||
| AID1079935 | Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] | |||
| AID1079933 | Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is | |||
| AID1079937 | Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] | |||
| AID1079946 | Presence of at least one case with successful reintroduction. [column 'REINT' in source] | |||
| AID1079948 | Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] | |||
| AID1079940 | Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] | |||
| AID1079938 | Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] | |||
| AID1079945 | Animal toxicity known. [column 'TOXIC' in source] | |||
| AID1079932 | Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] | |||
| AID1079944 | Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] | |||
| AID1079939 | Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] | |||
| AID1079936 | Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] | |||
| AID1079947 | Comments (NB not yet translated). [column 'COMMENTAIRES' in source] | |||
| AID1079934 | Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] | |||
| AID1079941 | Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (42)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 38 (90.48) | 18.7374 |
| 1990's | 4 (9.52) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 10.42
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (10.42) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (4.55%) | 5.53% |
| Reviews | 2 (4.55%) | 6.00% |
| Case Studies | 1 (2.27%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 39 (88.64%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||